Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vigil + irinotecan + temozolomide
- Development stage
- Discontinued
- Lead developer
- Gradalis
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules
- Administration
- Autologous Intradermal Or Intratumoral (Vigil), Oral (temozolomide, Irinotecan May Also Be Oral Or Intravenous), Intravenous (irinotecan)
01
Overview
This is an investigational **combination regimen** comprised of three agents: - **Vigil**: an autologous tumor cell immunotherapy, specifically a bi-shRNA furin and GM-CSF–augmented genetically modified autologous tumor cell vaccine designed to enhance immune response against the patient's tumor; - **Irinotecan**: a small molecule topoisomerase I inhibitor that interferes with DNA replication and transcription, causing cancer cell death; - **Temozolomide**: an oral alkylating agent that induces DNA methylation leading to tumor cell apoptosis. The regimen is being investigated as a treatment for relapsed or refractory Ewing's sarcoma, particularly in children and adolescents, with initial clinical development by Gradalis. Vigil is manufactured from an individual patient's tumor and administered in combination with standard chemotherapy (irinotecan and temozolomide) to potentially improve time to progression and survival compared to chemotherapy alone.
- Other names
- Vigil plus irinotecan and temozolomideVigil + Tem/Iri
02
Targets
DNAFurinCSF2R (Granulocyte-macrophage colony-stimulating factor receptor)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on Vigil + irinotecan + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vigil + irinotecan + temozolomide.